Plus Therapeutics, Inc. (PSTV)
Fuera de horario:
Plus Therapeutics, Inc.
4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
737 255 7194
https://plustherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 20
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, CEO & Director | 945.34k | N/D | 1963 |
| Mr. Andrew J. Sims CPA | VP of Finance & CFO | 498.51k | N/D | 1973 |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Medical Officer & Senior VP | 646.02k | N/D | 1948 |
| Ms. Desiree Smith | Corporate Controller, Principal Financial & Accounting Officer | N/D | N/D | 1964 |
| Dr. John K. Fraser | Chief Scientist | N/D | N/D | 1961 |
Descripción
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Plus Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
